Analysts Are Bullish on These Healthcare Stocks: Pacira Pharmaceuticals (PCRX), Rocket Pharmaceuticals (RCKT)

Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pacira Pharmaceuticals (PCRXResearch Report), Rocket Pharmaceuticals (RCKTResearch Report) and Kezar Life Sciences (KZRResearch Report) with bullish sentiments. Pacira Pharmaceuticals (PCRX) Wedbush analyst Liana Moussatos reiterated a Buy rating on Pacira Pharmaceuticals today and set a price target of $88.00. The companys shares closed last Thursday at $49.59, close to its 52-week low of $47.57.

According to TipRanks.com, Moussatos is ranked 0 out of 5 stars with an average return of -11.3% and a 30.1% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Liquidia Technologies, and Aerovate Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Pacira Pharmaceuticals with a $77.20 average price target, representing a 56.3% upside. In a report issued on October 20, Jefferies also initiated coverage with a Buy rating on the stock with a $66.00 price target.

See Insiders’ Hot Stocks on TipRanks >> Rocket Pharmaceuticals (RCKT) In a report released today, Gil Blum from Needham maintained a Buy rating on Rocket Pharmaceuticals, with a price target of $60.00. The companys shares closed last Thursday at $17.78.

According to TipRanks.com, Blum s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -24.9% and a 25.9% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Crispr Therapeutics AG, and Aeglea Biotherapeutics.

Currently, the analyst consensus on Rocket Pharmaceuticals is a Strong Buy with an average price target of $55.38, implying a 212.0% upside from current levels. In a report issued on November 1, BTIG also initiated coverage with a Buy rating on the stock with a $35.00 price target.

Kezar Life Sciences (KZR) In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Kezar Life Sciences, with a price target of $21.00. The companys shares closed last Thursday at $7.13.

According to TipRanks.com, Selvaraju s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -31.2% and a 19.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Fresh Tracks Therapeutics, and Oncternal Therapeutics.

Kezar Life Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $21.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Read More on PCRX:

Leave a Reply

Your email address will not be published. Required fields are marked *